Category: Research/Reports

Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds

August 17, 2023 Tom Mirga, Editor at Large Views

There has been a decline in the share of retail pharmacies that contract with 340B "core safety-net facilities," according to a JAMA Health Forum study.

The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Program Does Not Improve Hospital Inpatient Care for Medically Underserved Patients, HHS-Funded Study Finds

August 15, 2023 William Newton, Associate Editor/Senior Writer Views

A Health Services Research study with funding from a government agency suggested the 340B program does not improve hospital inpatient care quality.

The 340B drug pricing program does not improve inpatient care quality for underserved patients, a recent government-funded analysis concluded. A [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program

August 8, 2023 William Newton, Associate Editor/Senior Writer Views

GAO restated its controversial 2015 finding that 340B covered entities prescribe more drugs or more expensive drugs than necessary.

The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis

August 8, 2023 Rich Daly, Editor in Chief Views

A Moran Company study, funded by PhRMA, found 340B hospitals charge an average of 500% above acquisition costs for 20 high-cost drugs.

Hospitals charge, on average, 500% of their acquisition cost for 20 individual medicines that account for the largest share of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

On Deadline Day for Senate Feedback, Researchers in JAMA Urge 340B Provider Reporting, Tightening Eligibility, Preventing Drug Overcharges

August 3, 2023 Rich Daly, Editor in Chief Views

On the day a group of bipartisan Senators requested feedback from stakeholders, an influential academic and his colleagues published a series of recommendations to reform the 340B program in JAMA

A high-profile researcher and colleagues are urging a range of changes to the 340B program, including new provisions on transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Amid Historic Financial Challenges, 340B Proposed Payments Will ‘Make a Difference’ for Some Hospitals’ Budgets, Says Rating Official

August 1, 2023 Rich Daly, Editor in Chief Views

A Fitch Ratings webinar on the not-for-profit hospital sector discussed the financial implications of the proposed $9 billion lump sum Medicare payment to make up for five years of illegal 340B cuts.

As the not-for-profit hospital sector slowly emerges from its worst financial year in recent history, some of those organizations’ bottom [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B May Cause Providers to Buy More Expensive HIV Prevention Drugs, Conservative Policy Group Says

July 20, 2023 William Newton, Associate Editor/Senior Writer Views

The American Action Forum says in a new paper that 340B incentivizes providers to favor more expensive HIV medications, "raising costs for the rest of the health care system."

The 340B drug pricing program may incentivize hospitals and other covered entities to buy expensive preventative HIV medications over low-cost [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Commentary in NEJM Backs Making Hospitals Report Gross Profits from 340B

July 18, 2023 Tom Mirga, Editor at Large Views

To encourage nonprofit hospitals to do more for their communities, policymakers could examine how hospitals are using their gross profit from the 340B program, an opinion article in The New England Journal of Medicine says.

The 340B drug pricing program has evolved from a “buy low, sell low” program to help safety-net hospitals serve low-income [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

UPDATED: Contract Pharmacy Restrictions Cut $1.5 Billion in 340B Hospital Revenue, $8.4 Billion More Endangered, Report Says

July 13, 2023 Rich Daly, Editor in Chief Views

Drug manufacturers' 340B contract pharmacy restrictions have pulled $8.4 billion out of the savings hospitals achieve using contract pharmacies to dispense 340B drugs, a new 340B Health study found.

Early, limited versions of contract pharmacy restrictions for 340B hospitals cut their revenue by $1.5 billion in one year, according [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Studies Reach Different Conclusions About Whether Vulnerable Patients Benefit from 340B Savings

July 7, 2023 Tom Mirga, Editor at Large Views

Passing 340B drug discounts to patients with COPD so they can buy inhalers at a much lower cost yielded positive outcomes both for the patients and the hospitals that serve them, new research shows.

Two new studies—one by pharmacists at Ascension Via Christi health system in Kansas, the other by drug industry consulting and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live